MAINTENANCE INTRAVESICAL BCG IN INTERMEDIATE-, HIGH-RISK NONMUSCLE-INVASIVE BLADDER CANCER

被引：0
|
作者：
Muto, Satoru
Nagae, Mika
China, Toshiyuki
Koseki, Tatsuro
Kumamoto, Tomoka
Tokiwa, Shino
Yoshii, Takashi
Saito, Keisuke
Syuji, Isotani
Yamaguchi, Raizo
Ide, Hisamitsu
Horie, Shigeo
机构：
来源：
JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期
关键词：
D O I：
10.1016/j.juro.2011.02.2070
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1743
引用
收藏
页码：E700 / E700
页数：1
相关论文
共 50 条
  • [1] Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer
    van der Meijden, A. P. M.
    [J]. THESCIENTIFICWORLDJOURNAL, 2006, 6 : 2611 - 2616
  • [2] Sequential intravesical gemcitabine and docetaxel for BCG-naive high-risk nonmuscle-invasive bladder cancer.
    McElree, Ian Mitchell
    Steinberg, Ryan L.
    Mott, Sarah L.
    Martin, Alexander C.
    Richards, Jordan
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
    Basile, Giuseppe
    Pederzoli, Filippo
    Bandini, Marco
    Raggi, Daniele
    Gallina, Andrea
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Spiess, Philippe E.
    Necchi, Andrea
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 631 - 641
  • [4] A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
    Joshua, Julie Mariam
    Vijayan, Meenu
    Pooleri, Ginil Kumar
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 9
  • [5] Maintenance Therapy with Intravesical Bacillus CalmetteGurin in Patients with Intermediate- or High-risk Non-muscle-invasive Bladder Cancer
    Muto, Satoru
    Nakajima, Akiko
    Horiuchi, Akira
    Inoue, Masayuki
    China, Toshiyuki
    Saito, Keisuke
    Isotani, Shuji
    Hisasue, Shin-ichi
    Yamaguchi, Raizo
    Ide, Hisamitsu
    Horie, Shigeo
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (03) : 305 - 313
  • [6] Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alex C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    [J]. JOURNAL OF UROLOGY, 2022, 208 (03): : 589 - 597
  • [7] Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer - How much is enough?
    Decobert, Marc
    LaRue, Helene
    Harel, Francois
    Meyer, Francois
    Fradet, Yves
    Lacombe, Louis
    [J]. CANCER, 2008, 113 (04) : 710 - 716
  • [8] Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study
    Carando, Roberto
    Zazzara, Michele
    Cotrufo, Simone
    Ludovico, Giuseppe M.
    [J]. UROLOGIA INTERNATIONALIS, 2019, 103 (03) : 285 - 290
  • [9] Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
    Magalhaes, Joana C.
    Sousa, Maria
    Basto, Raquel
    Fraga, Teresa
    Gomes, Ines
    Fernandes, Catarina
    Mariano, Monica
    Paulo, Judy
    Madeira, Pedro
    Sousa, Gabriela
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [10] Intravesical chemohyperthermia with mitomycin c for intermediate- & high-risk non-muscle invasive bladder cancer
    Lai, B. C. H.
    Wen, Y. -C.
    Shih, H. -J.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 13 - 13
12345